RET Inhibitors in Oncology: Advancing Preclinical Insights to Early-Phase Impact
RET Inhibitors in Oncology: Advancing Preclinical Insights to Early-Phase Impact Read More »
START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center
START’s Site Network Solidifies its Global Leadership in Urological Cancer Trials The START Center for Cancer Research (“START”), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research Center (“CURC”) the premier urologic clinical research site specializing in genitourinary (GU) oncology. This acquisition strengthens
Together in the Fight Against Cancer: Thomas’ Story of Community and Care
“I was thinking about this the other night, one of the things that changed was I stopped flossing, because I figured, what’s the point?” Thomas recalls, sitting in a treatment room at START Mountain Region, reflecting on how his perspective had changed after getting his cancer diagnosis. Thomas, who works full-time as a bartender in
Together in the Fight Against Cancer: Thomas’ Story of Community and Care Read More »
Breaking Barriers in Blood Cancer Treatment: Insights on the Future of Malignant Hematology
A recent START webinar titled Malignant Hematology: Advancing Treatment in Blood Cancers, provided an in-depth look into the current advancements and challenges in treating hematological malignancies. Moderated by Dr. Andrew Sochacki, Associate Director for Hematology and Clinical Research at START Midwest, the session brought together leading experts to discuss myeloid malignancies, lymphoid malignancies, plasma cell
Advancing ADC Development: Expert Panel Explores Current Landscape and Future Opportunities
Antibody-drug conjugates (ADCs) are among the most promising innovations in cancer treatment today, combining the targeting precision of monoclonal antibodies with the potent killing power of cytotoxic drugs. In a recent webinar hosted by The START Center for Cancer Research (“START”), a distinguished panel of oncologists and researchers explored the science, challenges, and future directions
